| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.92▼ | 1.91▼ | 1.83▲ | 1.79▲ | 2.31▼ |
| MA10 | 1.95▼ | 1.84▲ | 1.80▲ | 1.87▲ | 2.36▼ |
| MA20 | 1.87▲ | 1.80▲ | 1.79▲ | 2.18▼ | 2.86▼ |
| MA50 | 1.81▲ | 1.79▲ | 1.84▲ | 2.51▼ | 7.58▼ |
| MA100 | 1.80▲ | 1.88▼ | 2.06▼ | 2.94▼ | N/A |
| MA200 | 1.88▼ | 2.22▼ | 2.58▼ | 3.51▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | 0.020▲ | 0.019▲ | -0.022▼ | 0.276▲ |
| RSI | 52.088▲ | 57.546▲ | 58.489▲ | 38.770▼ | 36.404▼ |
| STOCH | 42.853 | 75.238 | 54.596 | 19.197▼ | 23.230 |
| WILL %R | -56.000 | -50.909 | -50.909 | -78.824▼ | -90.931▼ |
| CCI | -42.399 | 73.235 | 208.349▲ | -28.624 | -101.163▼ |
|
Thursday, August 13, 2026 05:00 PM
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations ...
|
|
Wednesday, August 12, 2026 05:00 AM
Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to ...
|
|
Saturday, July 18, 2026 02:39 PM
Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/08/26 | 1.83 | 2.02 | 1.83 | 1.88 | 196,176 |
| 13/08/26 | 1.80 | 1.80 | 1.73 | 1.77 | 130,172 |
| 12/08/26 | 1.80 | 1.82 | 1.755 | 1.77 | 97,272 |
| 11/08/26 | 1.78 | 1.82 | 1.71 | 1.77 | 183,642 |
| 10/08/26 | 1.87 | 1.88 | 1.70 | 1.76 | 385,223 |
| 07/08/26 | 1.87 | 1.9422 | 1.85 | 1.87 | 103,220 |
| 06/08/26 | 2.02 | 2.02 | 1.80 | 1.85 | 519,509 |
| 05/08/26 | 1.92 | 2.04 | 1.86 | 2.00 | 325,297 |
| 04/08/26 | 2.03 | 2.0587 | 1.9997 | 2.03 | 383,259 |
| 03/08/26 | 2.09 | 2.09 | 1.9901 | 2.02 | 215,421 |
|
|
||||
|
|
||||
|
|